All companies
Visit website
XENSE
OperatingXENSE INC
Healthcare · Founded 2018
META CT, first in the world. Minimize time to diagnosis, treatment and wellness
Post-money valuation ⓘ
$100.4M
As of Sep 2024 · from XENSE Common Stock 2 · pre-money + amount raised, not a traded price
Total raised
$658,736
Across 2 rounds since 2022
Latest share price
$3.37
XENSE Common Stock 2 offering price
Financials
FY2020–FY2026 · from SEC filings · hover any figure for its source$0
−$1.0M
2020
$5
−$988K
2021
$0
−$825K
2022
$0
−$361K
2023
$0
−$318K
2024
$0
$370K
2025
$0
−$88K
2026
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Income statement
Revenue
$0
$5
$0
$0
$0
$0
$0
Cost of goods sold
$0
$15,466
$0
$0
$0
$0
$0
Gross margin
—
-309220%
—
—
—
—
—
Net income
-$1,021,526
-$988,204
-$825,241
-$361,315
-$318,434
$369,943
-$88,324
Taxes paid
$0
$0
$0
$35,958
$12,307
$10,792
$10,702
Balance sheet
Cash
$63
$13,752
$8,265
$73,908
$139,476
$73,672
$53,482
Accounts receivable
$0
$0
$0
$0
$0
$0
$0
Total assets
$122,030
$292,218
$244,963
$410,919
$553,557
$467,601
$595,828
Short-term debt
$157,043
$520,086
$626,241
$396,500
$374,405
$56,482
$56,482
Long-term debt
$531,943
$861,936
$1,120,153
$1,301,562
$1,343,098
$1,868,484
$1,407,526
Total liabilities
$688,986
$1,382,022
$1,746,394
$1,698,062
$1,717,503
$1,924,966
$1,464,008
Other
Headcount
—
2
3
3
4
—
3
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$228.0M
Valuation cap
$100.4M
post-money
XENSE Future Equity SAFE 1
XENSE Common Stock 2
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $471.2K / $618KInvestors 155Post-money $100.4M
Raised $187.5K / $1.1MInvestors 102Valuation cap $228M
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 4 of 4 annual reports (FY2022–FY2025)
155 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 11 filings on EDGARSource: ManualCIK 0001923723Share price $3.37
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.